Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30432
Title: Radiotheranostics in oncology: current challenges and emerging opportunities.
Austin Authors: Bodei, Lisa;Herrmann, Ken;Schöder, Heiko;Scott, Andrew M ;Lewis, Jason S
Affiliation: Molecular Imaging and Therapy
Olivia Newton-John Cancer Research Institute
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.. Department of Radiology, Weill Cornell Medical School, New York, NY, USA..
School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia..
German Cancer Consortium, University Hospital Essen, Essen, Germany.. Department of Nuclear Medicine, University of Duisburg-Essen, University Hospital Essen, Essen, Germany..
Department of Radiology, Weill Cornell Medical School, New York, NY, USA..
Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia..
Issue Date: Aug-2022
Date: 2022-06-20
Publication information: Nature Reviews. Clinical Oncology 2022; 19(8): 534-550
Abstract: Structural imaging remains an essential component of diagnosis, staging and response assessment in patients with cancer; however, as clinicians increasingly seek to noninvasively investigate tumour phenotypes and evaluate functional and molecular responses to therapy, theranostics - the combination of diagnostic imaging with targeted therapy - is becoming more widely implemented. The field of radiotheranostics, which is the focus of this Review, combines molecular imaging (primarily PET and SPECT) with targeted radionuclide therapy, which involves the use of small molecules, peptides and/or antibodies as carriers for therapeutic radionuclides, typically those emitting α-, β- or auger-radiation. The exponential, global expansion of radiotheranostics in oncology stems from its potential to target and eliminate tumour cells with minimal adverse effects, owing to a mechanism of action that differs distinctly from that of most other systemic therapies. Currently, an enormous opportunity exists to expand the number of patients who can benefit from this technology, to address the urgent needs of many thousands of patients across the world. In this Review, we describe the clinical experience with established radiotheranostics as well as novel areas of research and various barriers to progress.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30432
DOI: 10.1038/s41571-022-00652-y
ORCID: 0000-0001-6930-7383
0000-0001-7065-4534
0000-0002-6656-295X
Journal: Nature reviews. Clinical oncology
PubMed URL: 35725926
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35725926/
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

66
checked on Nov 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.